MX2009013131A - Moduladores de gamma secretasa. - Google Patents

Moduladores de gamma secretasa.

Info

Publication number
MX2009013131A
MX2009013131A MX2009013131A MX2009013131A MX2009013131A MX 2009013131 A MX2009013131 A MX 2009013131A MX 2009013131 A MX2009013131 A MX 2009013131A MX 2009013131 A MX2009013131 A MX 2009013131A MX 2009013131 A MX2009013131 A MX 2009013131A
Authority
MX
Mexico
Prior art keywords
compounds
gamma secretase
methods
secretase modulators
preparing
Prior art date
Application number
MX2009013131A
Other languages
English (en)
Inventor
John W Clader
Brian A Mckittrick
William J Greenlee
Zhaoning Zhu
Mark D Mcbriar
Xianhai Huang
Anandan Palani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009013131A publication Critical patent/MX2009013131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En sus muchas realizaciones, la presente invención proporciona una novedosa clase de compuestos heterocíclicos de la fórmula: (ver fórmula I) como moduladores de la gamma secretasa, métodos para la preparación de dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos para la preparación de formulaciones farmacéuticas que comprenden uno o más de dichos compuestos, y métodos de tratamiento, prevención, inhibición, o alivio de una o más de varias enfermedades asociadas con la sistema nervioso central usando dichos compuestos o composiciones farmacéuticas.
MX2009013131A 2007-06-01 2008-05-28 Moduladores de gamma secretasa. MX2009013131A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94140507P 2007-06-01 2007-06-01
US98448407P 2007-11-01 2007-11-01
PCT/US2008/006734 WO2008153793A2 (en) 2007-06-01 2008-05-28 Gamma secretase modulators

Publications (1)

Publication Number Publication Date
MX2009013131A true MX2009013131A (es) 2010-01-15

Family

ID=40084164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013131A MX2009013131A (es) 2007-06-01 2008-05-28 Moduladores de gamma secretasa.

Country Status (18)

Country Link
US (1) US8426403B2 (es)
EP (1) EP2152695A2 (es)
JP (1) JP5495331B2 (es)
KR (1) KR20100037053A (es)
CN (1) CN101809016A (es)
AR (1) AR066152A1 (es)
AU (1) AU2008263207B2 (es)
BR (1) BRPI0812170A8 (es)
CA (1) CA2689948A1 (es)
CL (1) CL2008001560A1 (es)
CO (1) CO6241123A2 (es)
EC (1) ECSP099776A (es)
IL (1) IL202315A0 (es)
MX (1) MX2009013131A (es)
PE (1) PE20090363A1 (es)
RU (1) RU2009148866A (es)
TW (1) TW200914459A (es)
WO (1) WO2008153793A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518080A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
CA2742317A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
JP2012508748A (ja) * 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2010056849A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
JP2012513400A (ja) * 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
US20120232108A1 (en) * 2009-06-16 2012-09-13 Xianhai Huang Gamma secretase modulators
EP2443121A2 (en) * 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
US20120245158A1 (en) * 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9598437B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
PE20171318A1 (es) 2015-02-03 2017-09-07 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
CN111741948B (zh) 2018-02-28 2023-11-10 日本烟草产业株式会社 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1065324A (en) 1974-05-13 1979-10-30 E.R. Squibb And Sons 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles
CH594667A5 (en) 1974-05-31 1978-01-13 Squibb & Sons Inc Hexahydro-2H-pyrazolo(4,3-C) pyridine derivs
US3979381A (en) 1975-08-11 1976-09-07 E. R. Squibb & Sons, Inc. Thiopyrano[4,3-c] pyrazoles
US4003890A (en) 1976-05-27 1977-01-18 E. R. Squibb & Sons, Inc. Benzylidene pyrano[4,3-c]pyrazoles
US4065617A (en) 1977-02-04 1977-12-27 E. R. Squibb & Sons, Inc. 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines
JP2002507611A (ja) * 1998-03-25 2002-03-12 ブリストル−マイヤーズ スクイブ カンパニー イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
ES2220753T3 (es) * 2000-03-20 2004-12-16 N-Gene Research Laboratories Inc. Derivados de amidoxina del acido propencarboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que los contienen.
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
KR20060023529A (ko) 2003-05-14 2006-03-14 토레이파인스 테라퓨틱스, 인코포레이티드 화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도
AU2004311577A1 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CA2567223A1 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CA2629745A1 (en) * 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
EA016464B1 (ru) * 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
AU2008263206A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
WO2010056849A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
AU2008263207A1 (en) 2008-12-18
WO2008153793A3 (en) 2009-03-19
BRPI0812170A2 (pt) 2014-12-02
EP2152695A2 (en) 2010-02-17
CO6241123A2 (es) 2011-01-20
AU2008263207B2 (en) 2013-10-03
KR20100037053A (ko) 2010-04-08
CA2689948A1 (en) 2008-12-18
AR066152A1 (es) 2009-07-29
WO2008153793A2 (en) 2008-12-18
PE20090363A1 (es) 2009-04-01
CL2008001560A1 (es) 2009-05-22
JP2010529015A (ja) 2010-08-26
AU2008263207A2 (en) 2010-01-28
BRPI0812170A8 (pt) 2016-02-10
US8426403B2 (en) 2013-04-23
ECSP099776A (es) 2010-01-29
CN101809016A (zh) 2010-08-18
JP5495331B2 (ja) 2014-05-21
US20100256128A1 (en) 2010-10-07
IL202315A0 (en) 2010-06-30
RU2009148866A (ru) 2011-07-20
TW200914459A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
MX2009012177A (es) Moduladores de gamma-secretasa.
MX2010001506A (es) Moduladores de gamma secretasa.
MX2009013131A (es) Moduladores de gamma secretasa.
MX2010003397A (es) Moduladores de la gamma secretasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
IN2012DN01233A (es)
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
TW200801003A (en) Novel compounds
PH12014500053A1 (en) Proteasome inhibitors
TW200740799A (en) Alpha2C adrenoreceptor agonists
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MY153915A (en) Organic compounds
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
TW200738659A (en) Novel compounds
MY148948A (en) Catecholamine derivatives and prodrugs thereof
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
MX2009013130A (es) Moduladores de gamma secretasa.
MX2016006509A (es) Compuestos triciclicos de piperidina.
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
MX2010001501A (es) Moduladores de gamma secretasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal